Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.11 USD | -3.21% | -10.59% | +19.89% |
14/03 | Top Premarket Gainers | MT |
13/03 | Indaptus Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 18.02M 1.5B |
---|---|---|---|---|---|
Net income 2024 * | -21M -1.75B | Net income 2025 * | -24M -2B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-1.06
x | P/E ratio 2025 * |
-1.48
x | Employees | 7 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 69.13% |
1 day | -3.21% | ||
1 week | -10.59% | ||
Current month | -5.80% | ||
1 month | -24.64% | ||
3 months | +27.11% | ||
6 months | -0.94% | ||
Current year | +19.89% |
Managers | Title | Age | Since |
---|---|---|---|
Michael Newman
FOU | Founder | 68 | 24/21/24 |
Jeffrey Meckler
CEO | Chief Executive Officer | 57 | 03/21/03 |
Nir Sassi
DFI | Director of Finance/CFO | 48 | 01/21/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
William Hayes
BRD | Director/Board Member | 58 | 03/21/03 |
Jeffrey Meckler
CEO | Chief Executive Officer | 57 | 03/21/03 |
Director/Board Member | 61 | 13/23/13 |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 2.11 | -3.21% | 8,086 |
25/24/25 | 2.18 | -7.23% | 29,204 |
24/24/24 | 2.35 | -5.62% | 49,611 |
23/24/23 | 2.49 | +2.05% | 7,360 |
22/24/22 | 2.44 | +3.39% | 4,186 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+19.89% | 18.02M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- INDP Stock